Procept Biorobotics Corp is a medical technology company that specializes in the development of innovative solutions for the treatment of prostate disease. The company was founded in 2012 and is headquartered in Redwood City, California, USA. Procept Biorobotics aims to revolutionize the treatment of prostate disease by utilizing advanced robotic technology.
The company's flagship product is the AquaBeam® System, also known as Aquablation therapy. The AquaBeam System is a minimally invasive surgical platform that uses a robotically controlled waterjet to precisely and autonomously remove prostate tissue in patients with benign prostatic hyperplasia (BPH). BPH is a common condition that causes an enlarged prostate, leading to urinary symptoms. Aquablation therapy provides an effective and targeted solution for patients suffering from BPH, offering potential benefits over traditional surgical methods.
Through its cutting-edge technology and focus on improving patient outcomes, Procept Biorobotics is making significant strides in the field of urology and advancing the standard of care for patients with prostate disease. The AquaBeam System has the potential to transform how urologists approach BPH treatment, offering a less invasive and more precise alternative to conventional therapies. As the company continues to grow and expand its technology, Procept Biorobotics is poised to become a key player in the global medical device market.